LIVER RFA IN CHINA
ZHONGSHAN HOSPITAL, EHBH, AND WHAT PATIENTS SHOULD KNOW
China treats more HCC patients annually than any other country. Its top hepatobiliary centres — Zhongshan, EHBH, and several others — have accumulated interventional oncology experience that is simply unavailable at most Western institutions. For international patients seeking liver RFA, China represents the highest-volume expertise at the lowest cost.
analyticsAt a Glance
- check_circleChina accounts for ~50% of global HCC cases — driving unmatched hepatobiliary expertise
- check_circleZhongshan Hospital (Shanghai): China's most internationally published liver cancer centre
- check_circleEHBH (Shanghai): highest volume liver cancer surgical and ablation programme in Asia
- check_circleCost 4–8× lower than Western equivalents with comparable or superior clinical outcomes
Why China Has Developed Unmatched Liver Cancer Expertise
China's dominant position in global hepatobiliary oncology is not a result of policy — it is a direct consequence of disease burden. Understanding this context explains why Chinese liver cancer centres have accumulated experience that Western institutions cannot replicate.
“A Chinese tier-1 academic hepatobiliary centre treats more HCC patients in one month than a typical large Western cancer centre treats in a year. Volume creates expertise — and in interventional oncology, expertise directly translates to outcomes.”
China's HCC Burden
Hepatitis B infection — the primary driver of HCC — affects approximately 80–90 million people in China. The resulting HCC burden is enormous: approximately 420,000 new HCC cases annually in China alone, representing ~50% of the global total. This patient population has created demand for liver cancer expertise — and the academic centres that serve this population have accumulated case volumes that are unprecedented globally.
Volume, Innovation, and Outcomes
High HCC volume drives clinical innovation: China has led the development of the TACE + RFA/MWA combination approach for intermediate HCC, multi-antenna simultaneous ablation techniques, and the integration of water-cooled antenna MWA systems. Chinese centres have published more large-series ablation outcome data for HCC than any other country — and this evidence base underpins global guideline recommendations.
Major Chinese Liver RFA Centres
Leading Chinese academic centres offering liver RFA — with specific programme strengths and international patient access.
| Centre | Location | Programme Strengths | International Access | Notable Feature |
|---|---|---|---|---|
| Zhongshan Hospital (Fudan University) | Shanghai | HCC RFA/MWA; TACE + ablation; hepatic resection; liver transplant; interventional oncology across all liver indications | Active international patient programme; English-capable team at senior level | Most internationally published Chinese liver cancer centre; home to key TACE+ablation RCTs |
| Eastern Hepatobiliary Surgery Hospital (EHBH) | Shanghai | World's highest-volume liver cancer surgical programme; extensive ablation programme alongside surgery | International patient service available; interpreter services | Largest liver cancer surgical programme globally; very high ablation volume in parallel |
| Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) | Beijing | Interventional oncology including liver ablation; comprehensive cancer centre | Accepts international patients; established pathways | China's national cancer centre — comprehensive multidisciplinary |
| Peking Union Medical College Hospital (PUMCH) | Beijing | Liver ablation within comprehensive hepatobiliary programme | International patient services; well-established | Strong hepatology-interventional collaboration; HBV-related HCC expertise |
| Sun Yat-sen University Cancer Center | Guangzhou | Strong in HCC (high Guangdong HCC prevalence) and also NPC — dual expertise | International patient programme especially for Cantonese-speaking diaspora | NPC + HCC dual expertise unique to Guangdong population |
| West China Hospital (Sichuan University) | Chengdu | HCC ablation; serving Southwest China's large HCC population | Growing international access; interpreter available | Very high volume; major academic centre for interior China |
Zhongshan Hospital and EHBH: What Makes Them Special
These two Shanghai institutions are the most internationally recognised Chinese liver cancer centres. Understanding what distinguishes them helps patients choose the right centre for their case.
Zhongshan Hospital: Published Evidence Leader
Zhongshan Hospital (Fudan University) has produced more internationally published liver ablation outcomes research than any other Chinese centre. Their interventional oncology team pioneered several of the key TACE + ablation protocols now used globally. English language communication at senior physician level. Combined hepatology-surgery-interventional radiology approach. Published outcomes data for >5,000 RFA/MWA procedures for HCC. Particularly strong for: TACE + ablation for 3–7 cm HCC; treatment of multiple small HCC nodules; technically challenging perivascular and subphrenic tumours.
EHBH: Surgical and Ablation Volume Leader
The Eastern Hepatobiliary Surgery Hospital (EHBH), affiliated with the Naval Medical University (formerly Second Military Medical University), holds the world record for annual liver cancer surgical volume. Their ablation programme operates alongside one of the world's most experienced hepatobiliary surgical teams. This means: EHBH patients can receive ablation AND surgical opinions simultaneously, surgery-to-ablation transition is seamless when cases require conversion, and the volume of complex cases gives the interventional team unmatched experience with difficult presentations.
What International Patients Should Know About Chinese Centre Access
Accessing care at Chinese tier-1 liver cancer centres is more practical than many international patients assume — but requires specific knowledge to navigate effectively.
Language: Interpreter Services Are Standard
Tier-1 Chinese academic centres have international patient departments with interpreter services. However, unlike Indian centres (where English is the care language throughout), routine clinical care in China is delivered in Mandarin. Medical records, consent forms, and discharge summaries are in Chinese — translated versions are provided for international patients. CancerFax arranges professional medical interpreters for all clinical encounters for patients navigating independently.
Wait Times and Appointment Scheduling
Popular centres like Zhongshan and EHBH have high domestic patient volumes. For international patients coordinated through the international patient department or through CancerFax, wait times are typically 1–3 weeks for initial evaluation and 2–4 weeks for procedure scheduling in non-urgent cases. Urgent cases with rapid disease progression can be fast-tracked. Pre-screening of medical records before travel confirms eligibility and prevents wasted journeys.
Payment: International Patients Pay Upfront
International patients at Chinese public academic centres pay upfront (before discharge) — typically in RMB or via international wire transfer. Insurance reimbursement claims are supported with detailed invoices and treatment summaries in English. CancerFax provides transparent itemised cost estimates before travel — covering procedure, hospitalisation, evaluation, and follow-up imaging costs.
Related China Access and RFA Topics
Related resources for Chinese centre access and liver RFA.
- RFA Costs in China and India: Detailed Comparison
- Accessing RFA Treatment in China or India Through CancerFax
- TACE + RFA Combination for Intermediate HCC: The Chinese Standard
- RFA for Liver Cancer (HCC): Eligibility and Outcomes
- China MWA Innovation: Advanced Antenna Systems
- Microwave Ablation in India: Centres and Access
Frequently Asked Questions
Common questions about accessing liver RFA at Chinese centres.
About Chinese Centres
Is the quality of liver RFA at Chinese centres comparable to Western hospitals?
For the specific indication of HCC ablation, China's tier-1 centres are not just comparable — they have a stronger outcomes evidence base than most Western centres. Zhongshan Hospital and EHBH have published long-term HCC ablation outcome data (5+ year follow-up, hundreds to thousands of patients) that benchmarks at or above leading Western published series. The volume of complex cases at Chinese hepatobiliary centres provides a technical depth that is genuinely difficult to match in low-HCC-prevalence Western countries.
How long would I need to stay in China for liver RFA?
Typical on-site stay for a planned liver RFA at a Chinese centre: evaluation day (day 1), procedure day (day 2–3), post-procedure observation and first follow-up imaging (days 3–7). Total stay 7–10 days for most cases. For TACE + RFA combination, add the TACE procedure plus the 2–3 week interval before RFA — total combined stay is typically 3–4 weeks for the full combination course, though some patients return for the two procedures separately.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
Liver Cancer? China's Leading Centres May Be the Right Option.
Upload your liver CT/MRI, AFP, and liver function tests. Our team will assess whether liver RFA at Zhongshan, EHBH, or another leading Chinese centre is appropriate — and manage all the logistics of international access.
For informational purposes only. Liver cancer treatment decisions require multi-disciplinary hepatobiliary team evaluation.